Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter and full year ended December 31, 2024.

Roche (SIX: RO, ROG; OTCQX: RHHBY) unveiled today its proprietary, breakthrough sequencing by expansion (SBX) technology, establishing a new category of next-generation sequencing. SBX chemistry, combined with an innovative sensor module, offers ultra-rapid, high-throughput sequencing that is both flexible and scalable for a broad range of applications.

Manufacturing investments have taken center stage in recent years — from some pharma giants ramping up GLP-1 manufacturing capacity to meet soaring demand to other companies focusing on advanced capabilities that could ensure an adequate supply of vaccines.

3.4.2 Abortion-Related Chromosome Testing Recurrent spontaneous abortion (RSA) refers to the loss of the fetus 3 or more times before 28 weeks of gestation according to the usual definition in China, but it is a..

Illumina, Inc. (NASDAQ: ILMN) today announced a new spatial technology program that will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale. Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina's spatial technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity. These capabilities are expected to drive expansion of spatial research and unlock applications and experiments that were previously not possible.

Home testing firm LetsGetChecked announced on Tuesday that its ImPress lancing device has received 510(k) clearance from the US Food and Drug Administration for professional use.

Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced a collaboration with Sumitomo Pharma America, Inc. (SMPA) to develop the FoundationOne®Heme platform as a companion diagnostic to identify patients with acute leukemia with a KMT2A rearrangement, also known as mixed lineage leukemia (MLL) rearrangement, or NPM1 mutations for potential treatment with SMPA’s enzomenib (DSP-5336), an investigational menin inhibitor.

Mindray’s Second Headquarters to Fully Launch Mindray’s Second Headquarters, located in Wuhan’s Optics Valley Bio-City, is set to be fully operational. As one of the world’s leading an..

bioMérieux, a company specializing in in vitro diagnostics, announced the launch of GENE-UP TYPER, a real-time PCR solution for rapid pathogen detection root cause analysis in the food industry.

The number of workers terminated by the Trump administration at the National Institutes of Health has been revised to 1,165, according to an NIH internal email seen by Reuters on Sunday, down from an initial 1,500.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has entered into a binding offer to purchase all equity interests in Stilla Technologies (“Stilla”). The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quarter of 2025.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2024.

Roche announced today that the Roche Elecsys® sFlt-1/PlGF ratio for preeclampsia has received 510(k) clearance from the United States Food and Drug Administration (FDA). The ratio is a prognostic test intended to stratify hospitalized pregnant women with hypertensive disorders of pregnancy into low- and high-risk categories for developing severe preeclampsia within two weeks of testing. Identifying patients at high risk for severe preeclampsia can lead to better prediction, earlier interventions and reduced adverse outcomes.

GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, and Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the initial phase of a program to improve provider access to GRAIL’s Galleri® multi-cancer early detection (MCED) test. Providers can now order the Galleri test directly from GRAIL through the Quest Diagnostics connectivity system. The Quest Diagnostics connectivity system enables providers in the United States to order and receive reports of laboratory tests electronically through Quest’s Quanum laboratory portal and more than 900 electronic health record (EHR) systems. More than 500,000 providers used the Quest connectivity system last year.

Original from: QuidelOrtho Fourth Quarter and Full-Year 2024 Results (all comparisons are to the prior year period) Fourth quarter 2024 revenue was $708 million, as reported · Non-respira..